Skip to content
Review Open access

Bacteriophage Therapy as a Viable Salvage Strategy for Extensively Drug-Resistant Gram-Negative Infections: A Narrative Review of Clinical Case Evidence, Regulatory Pathways, and the Barriers to Mainstream Adoption

Sep 2026 · INNOVAPATH · 0 citations · 20 references

Abstract

Backgrounds: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter, better known as the ESKAPE group are gram-negative bacteria that are multi-drug resistant. Due to this, ESKAPE bacterial infections have become increasingly difficult to treat, leading researchers to re-investigate potential abandoned therapies. Bacteriophage therapy is the use of bacteriophages, highly specific viruses that are able to target bacteria that otherwise would be impervious to other therapies. Despite this, bacteriophage therapy faces many barriers to mainstream adoption. Objective: Investigate barriers to mainstream adoption of bacteriophage therapy and address them using clinical evidence and meta analysis of regulatory pathways. Methods:  We conducted a rapid search of Pub Med/PMC and other key journals ranging from 2017 to January 2026 to perform a narrative review of bacteriophage therapy for drug-resistant gram-negative infections. We included peer-reviewed reviews and primary studies, covering both in vivo and in vitro evidence. The primary focus was the clinical efficacy and safety of phage therapy, with the regulatory pathways, and the barriers to its mainstream adoption.  Results:  Multiple studies recount patient cases in which bacteriophage treatment was a viable resource and aided in patient recovery. In gram-negative cases, phage treatment in the form of cocktails can address antibiotic resistance and result in a rapid recovery time. In some clinical trials where antibiotic administering could have been a course of treatment, phages were shown to be comparable to antibiotic treatment and were consistently regarded as potentially safe in clinical cases. Barriers identified were FDA standard regulations, costly development of a single therapy, complicated administration, and some evidence of worsening MDR. Conclusion:  Bacteriophages are a viable therapy to implement as a countermeasure to the rise of antibiotic resistant bacteria. They have proven to be viable throughout multiple studies and have shown to work in a wide variety of scenarios. And while some barriers are being worked on and other do not currently have a clear path to being solved, phage therapy does have a path forward that will allow humanity to overcome the challenges that exist with drug resistant bacteria.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.